Virzì Grazia Maria, Corradi Valentina, Panagiotou Anthi, Gastaldon Fiorella, Cruz Dinna N, de Cal Massimo, Clementi Maurizio, Ronco Claudio
Department of Nephrology, Dialysis and Transplantation, St. Bortolo Hospital, Via Rodolfi 37, 36100 Vicenza, Italy.
Int J Nephrol. 2010 Dec 21;2011:490795. doi: 10.4061/2011/490795.
The cardiorenal syndrome type 4 (Chronic Renocardiac Syndrome) is characterized by a condition of primary chronic kidney disease (CKD) that leads to an impairment of the cardiac function, ventricular hypertrophy, diastolic dysfunction, and/or increased risk of adverse cardiovascular events. Clinically, it is very difficult to distinguish between CRS type 2 (Chronic Cardiorenal Syndrome) and CRS type 4 (Chronic Renocardiac Syndrome) because often it is not clear whether the primary cause of the syndrome depends on the heart or the kidney. Autosomal dominant polycystic kidney disease (ADPKD), a genetic disease that causes CKD, could be viewed as an ideal prototype of CRS type 4 because it is certain that the primary cause of cardiorenal syndrome is the kidney disease. In this paper, we will briefly review the epidemiology of ADPKD, conventional and novel biomarkers which may be useful in following the disease process, and prevention and treatment strategies.
4型心肾综合征(慢性肾心综合征)的特征是原发性慢性肾脏病(CKD)导致心脏功能受损、心室肥厚、舒张功能障碍和/或不良心血管事件风险增加。临床上,很难区分2型心肾综合征(慢性心肾综合征)和4型心肾综合征(慢性肾心综合征),因为通常不清楚该综合征的主要病因是心脏还是肾脏。常染色体显性多囊肾病(ADPKD)是一种导致CKD的遗传病,可被视为4型心肾综合征的理想原型,因为心肾综合征的主要病因肯定是肾脏疾病。在本文中,我们将简要回顾ADPKD的流行病学、可能有助于跟踪疾病进程的传统和新型生物标志物,以及预防和治疗策略。